1.Chen, H.; Moriceau, S.; Joseph, A.; Mailliet, F.; Li, S.; Tolle, V.; Duriez, P.; Dardennes, R.; Durand, S.; Carbonnier, V.; et al. Acyl-CoA binding protein for the experimental treatment of anorexia. Sci Transl Med 2024, 16 (760), eadl0715.
2.Chen, H.; Martins, I.; Kroemer, G. The autophagy-repressive tissue hormone DBI/ACBP (diazepam binding inhibitor, acyl-CoA binding protein) suppresses anorexia. Autophagy 2024, 20 (12), 2827-2829.
3.Pan, H. *; Tian, A. L. *; Chen, H.; Xia, Y.; Sauvat, A.; Moriceau, S.; Lambertucci, F.; Motiño, O.; Zhao, L.; Liu, P.; et al. Pathogenic role of acyl coenzyme A binding protein (ACBP) in Cushing's syndrome. Nat Metab 2024, 6 (12), 2281-2299.
4.Montégut, L.; Liu, P.; Zhao, L.; Pérez-Lanzón, M.; Chen, H.; Mao, M.; Zhang, S.; Derosa, L.; Naour, J. L.; Lambertucci, F.; et al. Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance. Mol Cancer 2024, 23 (1), 187.
5.Motiño, O.; Lambertucci, F.; Joseph, A.; Durand, S.; Anagnostopoulos, G.; Li, S.; Carbonnier, V.; Nogueira-Recalde, U.; Montégut, L.; Chen, H.; et al. ACBP/DBI neutralization for the experimental treatment of fatty liver disease. Cell Death Differ 2024.
6.Anagnostopoulos, G.; Saavedra, E.; Lambertucci, F.; Motiño, O.; Dimitrov, J.; Roiz-Valle, D.; Quesada, V.; Alvarez-Valadez, K.; Chen, H.; Sauvat, A.; et al. Inhibition of acyl-CoA binding protein (ACBP) by means of a GABA(A)Rγ2-derived peptide. Cell Death Dis 2024, 15 (4), 249.
7.Montégut, L.; Derosa, L.; Messaoudene, M.; Chen, H.; Lambertucci, F.; Routy, B.; Zitvogel, L.; Martins, I.; Kroemer, G. Benzodiazepines compromise the outcome of cancer immunotherapy. Oncoimmunology 2024, 13 (1), 2413719.
8.Montégut, L.*; Joseph, A. *; Chen, H. *; Abdellatif, M. *; Ruckenstuhl, C.; Motiño, O.; Lambertucci, F.; Anagnostopoulos, G.; Lachkar, S.; Dichtinger, S.; et al. High plasma concentrations of acyl-coenzyme A binding protein (ACBP) predispose to cardiovascular disease: Evidence for a phylogenetically conserved proaging function of ACBP. Aging Cell 2023, 22 (1), e13751.
9.Montégut, L. *; Joseph, A. *; Chen, H. *; Abdellatif, M. *; Ruckenstuhl, C.; Martins, I.; Madeo, F.; Kroemer, G. DBI/ACBP is a targetable autophagy checkpoint involved in aging and cardiovascular disease. Autophagy 2023, 19 (7), 2166-2169.
10.Zhao L, Liu P, Mao M, Zhang S, Bigenwald C, Dutertre CA, Lehmann CHK, Pan H, Paulhan N, Amon L, Buqué A, Yamazaki T, Galluzzi L, Kloeckner B, Silvin A, Pan Y, Chen H, Tian AL, Ly P, Dudziak D, Zitvogel L, Kepp O, Kroemer G. BCL2 Inhibition Reveals a Dendritic Cell-Specific Immune Checkpoint That Controls Tumor Immunosurveillance. Cancer Discov 2023, 13 (11), 2448-2469.
11.Zhang, S.; Zhao, L.; Guo, M.; Liu, P.; Li, S.; Xie, W.; Tian, A. L.; Pol, J. G.; Chen, H.; Pan, H.; et al. Anticancer effects of ikarugamycin and astemizole identified in a screen for stimulators of cellular immune responses. J Immunother Cancer 2023, 11 (7).
12.Montégut, L. *; Chen, H. *; Bravo-San Pedro, J. M.; Motiño, O.; Martins, I.; Kroemer, G. Immunization of mice with the self-peptide ACBP coupled to keyhole limpet hemocyanin. STAR Protoc 2022, 3 (1), 101095.
13.Motiño, O.; Lambertucci, F.; Anagnostopoulos, G.; Li, S.; Nah, J.; Castoldi, F.; Senovilla, L.; Montégut, L.; Chen, H.; Durand, S.; et al. ACBP/DBI protein neutralization confers autophagy-dependent organ protection through inhibition of cell loss, inflammation, and fibrosis. Proc Natl Acad Sci U S A 2022, 119 (41), e2207344119.
14.Anagnostopoulos, G.; Motiño, O.; Li, S.; Carbonnier, V.; Chen, H.; Sica, V.; Durand, S.; Bourgin, M.; Aprahamian, F.; Nirmalathasan, N.; et al. An obesogenic feedforward loop involving PPARγ, acyl-CoA binding protein and GABA(A) receptor. Cell Death Dis 2022, 13 (4), 356.
15.Joseph, A.; Chen, H.; Anagnostopoulos, G.; Montégut, L.; Lafarge, A.; Motiño, O.; Castedo, M.; Maiuri, M. C.; Clément, K.; Terrisse, S.; et al. Effects of acyl-coenzyme A binding protein (ACBP)/diazepam-binding inhibitor (DBI) on body mass index. Cell Death Dis 2021, 12 (6), 599.
16.Deng, J.; Tian, A. L.; Pan, H.; Sauvat, A.; Leduc, M.; Liu, P.; Zhao, L.; Zhang, S.; Chen, H.; Taly, V.; et al. Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype. Cell Death Dis 2021, 12 (11), 978.